ReviewPharmaceutics2020
Liposomes for Enhanced Bioavailability of Water-Insoluble Drugs: In Vivo Evidence and Recent Approaches.
Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanoparticles in gynecologic cancers: a bibliometric and visualization analysis.Frontiers in oncology · 2024Pooled it
- Advances in veterinary drug and vaccine delivery: from conventional delivery methods to innovative transdermal approaches.Drug delivery and translational research · 2026Review
- Nanotechnology-based immunotherapy: integrating Artificial Intelligence (AI) with current strategies in combating brain cancer disease.Journal of the Egyptian National Cancer Institute · 2026Review
- Development and in vitro evaluation of teicoplanin PEGylated (TEC-PEGylated) niosomes for antimicrobial and anti-biofilm activity against vancomycin-intermediate Staphylococcus aureus (VISA).BMC biotechnology · 2026Article
- Liposomal Formulation of Bioactive Substances fromInternational journal of molecular sciences · 2026Article
- Nanotechnology for efficient delivery of TCM active ingredients in treating brain diseases.Materials today. Bio · 2026Review
- CaP-Coated Cyclosporine A Liposomes Formulated as an Inhalable Dry Powder for Lung Inflammatory Diseases.Pharmaceutics · 2026Article
- Formulation Strategies to Enhance the Solubility of Poorly Water-Soluble Drugs and Phytochemicals: Current Advances and Challenges.Pharmaceutics · 2026Review
- Tumor-targeted liposomal RNAi therapy suppresses breast cancer and modulates tumor microenvironment.Journal of nanobiotechnology · 2026Article
- Grape Pomace Extract-Loaded Liposomes Enriched Cream Formulations for Skincare.Antioxidants (Basel, Switzerland) · 2026Article
- Nanostructured Lipid Carriers as Physicochemical Modulators of Complex Natural Extracts: Release Behavior and Bile-Induced Remodeling in Biorelevant Media.Molecules (Basel, Switzerland) · 2026Article
- Effect of niosome formation with chitosan coating on the stability and absorption of orally administered vesicular ursolic acid.Journal of materials science. Materials in medicine · 2026Article
- Liposomal Delivery ofPharmaceutics · 2026Article
- Review
- Recent advances in the delivery of natural-product antioxidants for the treatment of breast cancer.Frontiers in bioengineering and biotechnology · 2026Review
- Nanotechnology-donated ischemic stroke therapeutics: evolving strategies from the basic to the cutting-edge.Theranostics · 2026Review
- Recent advances in the detection and treatment of hydatid cysts by nanomaterial-based carriers.Iranian journal of basic medical sciences · 2026Review
- Enhancement of antioxidant and cytotoxicity by nanoliposome formulation of pentagamavunon-6 in breast cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Lipid-based nanocarriers in combination chemotherapy: a promising strategy for advanced skin cancer management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Improved Encapsulation and Potential of Liposomal Tosufloxacin via Inclusion in Cyclodextrin.AAPS PharmSciTech · 2025Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
It has been known that a considerable number of drugs in clinical use or under development are water-insoluble drugs with poor bioavailability (BA). The liposomal delivery system has drawn attention as one of the noteworthy approaches to increase dissolution and subsequently absorption in the gastrointestinal (GI) tract because of its biocompatibility and ability to encapsulate hydrophobic molecules in the lipid domain. However, there have been several drawbacks, such as structural instability in the GI tract and poor permeability across intestinal epithelia because of its relatively large size. In addition, there have been no liposomal formulations approved for oral use to date, despite the success of parenteral liposomes. Nevertheless, liposomal oral delivery has resurged with the rapid increase of published studies in the last decade. However, it is discouraging that most of this research has been in vitro studies only and there have not been many water-insoluble drugs with in vivo data. The present review focused on the in vivo evidence for the improved BA of water-insoluble drugs using liposomes to resolve doubts raised concerning liposomal oral delivery and attempted to provide insight by highlighting the approaches used for in vivo achievements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.